Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

被引：1
|
作者：
Hanes, Vladimir [1 ]
Pan, Jean [1 ]
Mytych, Daniel T. [1 ]
Chien, David [1 ]
Chow, Vincent [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128621
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3520
引用
收藏
页数：3
相关论文
共 25 条
  • [1] RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB
    Kaur, P.
    Chow, V.
    Zhang, N.
    Markus, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 714 - 714
  • [2] Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects
    Chow, Vincent
    Mytych, Daniel T.
    Das, Shyamal
    Franklin, Janet
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (09): : 863 - 873
  • [3] Efficacy of Parallel and Crossover Analysis As Well As Pharmacokinetic Similarity Were Confirmed between ABP 959 and Eculizumab Reference Product in Patients with PNH
    Kulasekararaj, Austin
    Lanza, Francesco
    Arvanitakis, Alexandros
    Langemeijer, Saskia M. C.
    Chonat, Satheesh
    Cao, Jia
    Chow, Vincent
    Henary, Haby
    BLOOD, 2023, 142
  • [4] Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
    Genovese, Mark
    Sanchez-Burson, Juan
    Balazs, Eva
    Everding, Andrea
    Oh, MyungShin
    Fanjiang, Gary
    Cohen, Stanley
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [5] A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris(R)) in healthy male subjects
    Chow, Vincent
    Pan, Jean
    Chien, David
    Mytych, Daniel T.
    Hanes, Vladimir
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (01) : 66 - 74
  • [6] Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects
    Chow, Vincent
    Oh, MyungShin
    Gessner, Melissa A.
    Fanjiang, Gary
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 246 - 255
  • [7] RESULTS FROM A RANDOMIZED, SINGLE-BLIND, SINGLE-DOSE, PARALLEL-GROUP STUDY IN HEALTHY SUBJECTS DEMONSTRATING PHARMACOKINETIC SIMILARITY BETWEEN ABP 710 AND INFLIXIMAB
    Krishnan, E.
    Chow, V.
    Zhang, N.
    Kaliyaperumal, A.
    Kaur, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1181 - 1181
  • [8] A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
    Lee, Hyun A.
    Jang, Hyerin
    Jeong, Deokyoon
    Kim, Younsoo
    Fuhr, Rainard
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (06) : 269 - 279
  • [9] Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
    Kaur, Primal
    Chow, Vincent
    Zhang, Nan
    Krishnan, Eswar
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] The relationship between menopausal status and urinary symptoms: Results from the BACH study
    Hall, Susan A.
    Link, Carol L.
    Schiff, Isaac
    McKinlay, John B.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (06): : 1082 - 1082
123